PRESS RELEASE



Date: 13th February 2023

VaRi Bioscience GmbH announces collaboration with Mithra CDMO for the development of VR102, VaRi's long-acting estriol-releasing vaginal ring

Berlin, Germany, 13. February 2023 - VaRi Bioscience GmbH, an innovative Women's Health company in the Berlin-Brandenburg cluster region, focuses on vaginal ring drug delivery. Today VaRi Bioscience announces the signature of a collaboration agreement with Mithra CDMO, a Belgian company dedicated to Women's Health. According to the agreement, VaRi Bioscience's innovative vaginal ring VR102 will be developed in Mithra's plant in Liège.

VaRi Bioscience has decided for a cooperation with Mithra because of their experience in the development and production of complex and long-acting innovative products using medical polymer technology. "We are very happy to collaborate with Mithra in the VR102 development. The collaboration brings us a decisive step closer to the start of the phase IIB study of VR102", explained Klaus Nickisch, CEO of VaRi Bioscience. VR102 is a long-acting 3-month estriol (E3)-releasing vaginal ring for the treatment of vulvovaginal atrophy (VVA) with purely local efficacy, which will be clinically demonstrated. Under the terms of the collaboration, Mithra will be responsible for the development of the clinical supplies.

VVA is a common condition of thinning and drying of the vaginal walls that may occur when estrogen levels drop. Vaginal atrophy can occur at any time in a women's life cycle but most often after menopause or medically induced estrogen deprivation (e.g., breast cancer therapy, harsh endometriosis therapies). Up to 50% of postmenopausal women experience symptoms of VVA such as, e.g., vaginal dryness and discharge, recurrent urinary tract infections, decreased vaginal lubrication, and pain during intercourse.

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women's health and beyond. www.mithra.com

About VaRi Bioscience GmbH

VaRi Bioscience GmbH is an innovative German biotech company that is pioneering novel approaches to serve high unmet medical needs in various therapeutic areas of Female Health. The company focuses on the discovery, development and commercialization of innovative products centered around its unique, IP-protected approach of novel drug delivery concepts.

Please visit our website: www.vari-bioscience.com or connect with us on LinkedIn

For more Information, Please contact:

Klaus Nickisch, Ph.D. (CEO): +49 174 1510 148, knickisch@vari-bioscience.com Kerstin Bode-Greuel, MD, PhD. (Head of BD): +49 170 5265 883, kbode-greuel@vari-bioscience.com